IPITA continues to be at the vanguard of beta cell replacement therapy for treating diabetes, and this was again evident in their sponsorship and the success of the 4^th Summit on Stem Cell-Derived Beta Cells that was held in Cambridge, MA, USA on April 24-25, 2023. With the co-sponsorship of the Juvenile Diabetes Research Foundation and the Harvard Stem Cell Institute, the Summit brought over 180 top experts together to share ongoing work aimed towards refining stem cell islets as a biological therapy for T1D and to chart the path forward for the field. The Summit was focused on gaining insights from islet biology including single-cell multi-omics, and how this knowledge might be applied toward optimizing differentiation protocols and deriving methods to eliminate off-target cells. The meeting also included sessions devoted to discussing technologies designed to eliminate the need for immunosuppression or reduce immunogenicity, such as CRISPR genome engineering. An update was provided on an ongoing clinical trial and over 30 abstracts were presented. Finally, a critical aspect of the meeting was a panel discussion on the eligibility criteria for stem cell islet trials that involved key stakeholders including patients, endocrinologists, regulatory experts, and scientists.